Peptide Library/Growth Hormone Secretagogues/Tesamorelin

Tesamorelin

FDA ApprovedExtensive Research

Also known as: Egrifta · TH9507

An FDA-approved GHRH analog specifically indicated for reducing visceral adipose tissue, with potent effects on body composition.

Overview

Tesamorelin is a synthetic analog of growth hormone releasing hormone (GHRH) that has been modified with a trans-3-hexenoic acid group to improve its stability and potency. It is the only GHRH analog currently FDA-approved (as Egrifta) for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Tesamorelin stimulates the pituitary gland to produce growth hormone, which in turn promotes lipolysis (fat breakdown), particularly of visceral adipose tissue — the metabolically dangerous fat that surrounds internal organs. Clinical trials demonstrated that Tesamorelin reduced trunk fat by approximately 18% over 26 weeks, with significant improvements in triglyceride levels and patient-reported body image.

Beyond its approved indication, Tesamorelin is increasingly used off-label in anti-aging and body composition optimization protocols. It has also shown neuroprotective properties, with research suggesting it may improve cognitive function in older adults at risk for Alzheimer's disease.

Mechanism of Action

Binds to GHRH receptors on pituitary somatotrophs with enhanced stability due to the trans-3-hexenoic acid modification. Stimulates endogenous GH production, which activates hepatic IGF-1 production and promotes lipolysis in visceral adipose tissue.

Key Benefits

FDA-approved for visceral fat reduction

Significant reduction in trunk/abdominal fat

Improved triglyceride levels

Potential neuroprotective effects

Preservation of lean body mass

Improved body image and quality of life

Potential Side Effects

Injection site reactions

Joint pain

Peripheral edema

Paresthesia

Elevated blood glucose

Common Stacks

This peptide is commonly combined with the following compounds for synergistic effects:

IpamorelinAOD-9604BPC-157

Known Interactions

The following interactions have been documented for Tesamorelin. Always consult a healthcare professional before combining compounds.

Synergistic (1)

IpamorelinSynergistic

Tesamorelin (GHRH analog) + Ipamorelin (GHRP) is a clean GH-boosting stack. Tesamorelin is FDA-approved for lipodystrophy and pairs well with Ipamorelin's selective GH release.

View all compound interactions

Scientific References

Tesamorelin for the Treatment of Visceral Adiposity in HIV

Falutz J, Allas S, Blot K, et al.

New England Journal of Medicine (2007)

Tesamorelin Effects on Cognition in Older Adults

Baker LD, Barsness SM, Borber S, et al.

Alzheimer's & Dementia (2019)

Quick Reference

Typical Dose

2 mg

Frequency

Once daily

Route

Subcutaneous injection

Half-Life

~26 minutes (but effects last longer due to GH cascade)

Cycle Length

26 weeks (per FDA protocol); can be extended

FDA Status

FDA approved (Egrifta) for HIV-associated lipodystrophy

Need to calculate dosing?

Use our reconstitution calculator to determine exact syringe measurements.

Open Calculator

This information is for educational purposes only. Consult a qualified healthcare professional before using any peptide. Dosing information reflects commonly reported protocols and may not be appropriate for everyone.

Related Peptides in Growth Hormone Secretagogues

CJC-1295

A long-acting growth hormone releasing hormone (GHRH) analog that stimulates sustained, pulsatile GH release from the pituitary gland.

Ipamorelin

A highly selective growth hormone secretagogue that stimulates GH release without significantly affecting cortisol, prolactin, or appetite.

Sermorelin

A bioidentical GHRH analog representing the first 29 amino acids of natural GHRH, providing the most physiologically natural approach to GH stimulation.